<DOC>
	<DOCNO>NCT00546936</DOCNO>
	<brief_summary>The purpose study evaluate change visual activity ranibizumab Photodynamic Therapy ( PDT ) patient choroidal neovascularization ( CNV ) secondary presume ocular histoplasmosis</brief_summary>
	<brief_title>Ranibizumab Versus PDT Presumed Ocular Histoplasmosis</brief_title>
	<detailed_description />
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subfoveal CNV due presume ocular histoplasmosis less 1 year duration Ability provide write informed consent comply study assessment full duration study Age great equal 21 year age CNV lesion &lt; 5400 micron diameter Best correct visual acuity 20/4020/320 Birth control therapy female childbearing potential Subfoveal NCV due tp presume ocular histoplasmosis &gt; 1 year Pregnancy lactation premenopausal woman use adequate contraception Prior enrollment study Any condition Investigator believe would pose significant hazard subject Participation another simultaneous medical investigation trial Participation another trial previous trial ranibizumab Avastin Any concurrent ocular condition study eye ( cataract , diabetic retinopathy ) could require medical surgical intervention ifa allow progress , could likely contribute loss least 2 Snellen equivalent line BCVA 12month study period Previous panretinal photocoagulation Previous steroid PDT 3 month Previous participation study investigational drug within 30 day precede Day 0 Prior participation Genentech ranibizumab clinical trial Previous treatment intravitreally ( either eye ) intravenously administer Avastin within 3 month Previous use Macugen study eye within 3 month Prior submacular surgery</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Histoplasmosis</keyword>
</DOC>